Earlier studies in transplantation showed that administration of Gal-1 in rats prolonged renal allograft survival by inhibiting the CD8+ T cell response and reduced the incidence of graft versus host disease (GVHD) in an allo-HCT model (24, 33). Here, CD8A is linked to graft versus host disease.